The fourth episode of Orthocell’s ‘Meet the Board’ video series is now live – featuring Independent Director, Dr. Ravi Thadhani.
Appointment of Key US Executives to Lead Remplir™ Launch
Orthocell has appointed two experienced US-based executives to drive the market launch and sales of Remplir™ following the expected US FDA approval in the first quarter of 2025.
Equity Mates Podcast
Orthocell has been named as a biotech stock to watch on a recent episode the Equity Mates Investing Podcast.
The West Australian | Orthocell confirms record $17 million raising to launch in the US
Orthocell’s record $17 million capital raise has been featured in The West Australian newspaper in an article titled “Orthocell confirms record $17 million raising to launch in the US” by journalist Sean Smith.
$17 million placement to fund US launch of Remplir™ and drive further growth
Orthocell has today announced that it has received firm commitments for a $17 million capital raising via an institutional placement.
Meet The Board | Chairman, John Van Der Wielen
The third episode of Orthocell’s ‘Meet the Board’ video series is now online – featuring Chairman, John Van Der Wielen.
Executive Series | Meet The Board | Professor Fiona Wood AM
In the second instalment of the ‘Meet The Board’ video series, we meet Professor Fiona Wood, a world-renowned plastic and reconstructive surgeon, and valued member of the Orthocell Board.
Orthocell Receives Regulatory Approval for Remplir™ in Singapore
Orthocell has received regulatory approval from the Health Sciences Authority (HSA) in Singapore, allowing the Company to commence sales of its market leading nerve repair product, Remplir™
Orthocell Reports Second Consecutive Quarter of Record Revenue
Orthocell has today announced continued growth in sales of its market-leading medical devices, Striate+™ and Remplir™.
VIDEO | Meet The Board | CEO & MD, Paul Anderson
The first episode of Orthocell’s ‘Meet the Board’ video series is now live – featuring CEO & MD, Paul Anderson.